Cytomegalovirus (CMV) DNA load was analyzed as a marker for relapse of CMV infection in 24 solid organ transplant patients with CMV infection or disease who received a fixed 14-day course of intravenous ganciclovir. Viral load was measured in blood samples obtained before and at the completion of treatment. Eight (33%) of 24 patients developed relapsing CMV infection. Median pretreatment viral loads were higher in the relapsing group (80,150 copies/10 6 leukocytes) than in the nonrelapsing group (5500 copies/10 6 leukocytes; ). P = .007 The relapsing group also had persistent detectable viral DNA (median, 5810 copies/10 6 leukocytes) after treatment, whereas it was undetectable in the nonrelapsing group ( ). P ! .0001 Primary CMV infection (seronegative recipients of seropositive organs, D+RϪ) was an independent marker for CMV relapse ( ), and these patients had higher pre-and post-P = .03 treatment viral loads than did non-D+/RϪ patients ( and , respectively). P ! .0001 P = .0014 CMV DNA load is a useful marker for individualizing antiviral treatment of CMV infection in solid organ transplant recipients.
led to the correlation of high viral loads with more severe forms of CMV disease [6] [7] [8] [9] . Because solid organ transplant patients fulfill many of the epidemiologic risk factors that predispose to relapsing CMV disease, it is likely that viral load could be used as a marker of relapsing CMV disease. To address this, a prospective study was initiated to investigate whether viral load quantification by means of an automated and reproducible polymerase chain reaction (PCR) technology is of clinical value in determining the optimal duration of antiviral therapy for confirmed CMV infection following organ transplantation.
Patients and Methods
Patients, study design, and definitions. Heart, liver, and kidney allograft transplantation patients at our institution from July 1997 through December 1998 were eligible. Induction immunosuppression and CMV prophylaxis regimens differed according to specific organ transplant programs.
During the first 12 weeks after transplantation, allograft recipients were prospectively surveyed for CMV viremia and CMV disease by use of weekly viral cultures in blood and routine clinical evaluation. During and beyond this period, additional blood and/ or tissue specimens were obtained for culture and/or microscopic examination when patients were suspected of developing CMV infection. Documentation of CMV infection or disease (see definitions below) in these patients any time after transplantation prompted their enrollment. Patients who had begun receiving empirical antiviral treatment for suspected CMV infection, who had developed prior episodes of CMV infection or disease, or who were aged р10 years were excluded. All patients enrolled in the study received ganciclovir, 5 mg/kg intravenously every 12 h for 14 days, which was adjusted to renal function as recommended by the man- ufacturer. Blood (5 mL) was obtained before the first dose of ganciclovir (pretreatment sample) and at day 14 of treatment, coinciding with the completion of antiviral therapy (posttreatment sample). These samples were processed for viral culture (shell vial technique) and viral load measurement (see below). Clinicians caring for such patients were blinded to the results of the latter test. CMV infection and disease were defined as outlined by previous international CMV workshops [10] . Asymptomatic viremia was defined as culture of virus from blood in the absence of symptoms. CMV disease included both symptomatic viremia (also termed CMV syndrome) and CMV tissue-invasive disease. Relapsing CMV was defined as the reappearance of CMV infection or disease after completion of 14 days of antiviral therapy (documentation of clinical cure and absence of CMV in the blood as determined by cell cultures). The study end point was either CMV disease relapse or the end of 4 months of follow-up after the initial episode of CMV infection, whichever came first. Standard tables were 4 ϫ 4 constructed for the values obtained. For the determination of statistical significance, Fisher's exact test was used.
Quantitative CMV PCR. The COBAS Amplicor CMV monitor test (Roche Diagnostics, Branchburg, NJ) was used for PCR. The plasma fraction was separated by centrifugation and stored in 500-mL aliquots at Ϫ70ЊC. Buffy coat was extracted with Histopaque (Sigma, St. Louis). Mononuclear cells and granulocytes were separated, washed twice in PBS, counted, resuspended in aliquots of , pelleted by centrifugation, and stored at Ϫ70ЊC. 2 ϫ 10 Nucleic acid was extracted from 200 mL of plasma or from cell pellets containing cells and was then added to 600 mL of 5 2 ϫ 10 guanidinium thiocyanate lysis reagent, to which an internal quantitation standard with 288 copies/mL (lower limit of detection) was added. DNA was then precipitated with 800 mL of isopropanol by centrifugation, washed once with 1 mL of 70% ethanol, and resuspended in 400 mL of specimen diluent. Three controls with values that span the dynamic range of the assay were included with each batch, which consisted of 21 specimens and 3 controls: a negative control, a low-positive CMV control ( to cop- 3 4 1.20 ϫ 10 1.90 ϫ 10 ies/mL), and a high-positive control ( and copies/ 4 5 5 ϫ 10 4.40 ϫ 10 mL).
After specimen preparation, 50 mL (equivalent to cells/ 4 2.5 ϫ 10 PCR input) of each processed specimen or control was added to 50 mL of master mix containing dNTPs, Taq polymerase, magnesium, uracil-N-glycosylase, biotinylated CMV primers (LC383 and LC342), and salts in separate amplification tubes. The primers amplified a sequence of ∼362 bp within the CMV DNA polymerase gene UL54. Amplification rings were then placed in the COBAS instrument; amplification, denaturation, amplicon detection, and quantitation proceeded in an automated fashion. The measurement of CMV DNA copies is based on the comparison of amplicon to the quantitation standard present in each amplification reaction. Final test results are reported as a numeric concentration in copies per milliliter of plasma or as copies per 10 6 leukocytes.
Results
Characteristics of the 24 patients who fulfilled study inclusion criteria are shown in table 1. Relapse of CMV infection or disease occurred in 8 (33.3%) of 24 patients between 22 and 65 days (median, 33) after completing the 14-day course of iv ganciclovir therapy for the initial episode of CMV infection or disease. During the initial episode, 10 (41.6%) of 24 patients presented with asymptomatic infection and 14 (58.3%) with CMV disease. The clinical presentation (asymptomatic infection or disease) did not discriminate patients who subsequently had relapses ( ). However, classification of subjects by P = 1.0 CMV donor-recipient serostatus did discriminate patients at risk for relapsing CMV disease. Six of 10 CMV Dϩ/RϪ patients had a relapse episode, compared with 2 (14%) of 14 non-Dϩ/RϪ patients ( ). Only 1 patient of the non-Dϩ/ P = .03 RϪ group who relapsed had an episode of allograft rejection requiring OKT3 treatment before the first episode of CMV.
For all 24 patients, pretreatment viral load ranged from 565 to 190,000 copies/10 6 leukocytes (median, 17,600 copies/10 6 leukocytes) and from 0 to 46,100 copies/mL (median, 2650 copies/ mL) of plasma. From the same pretreatment specimen, CMV DNA copies were higher in most instances (73%) in leukocytes than in plasma. In the relapse group, pretreatment viral loads ranged from 7610 to 190,000 copies/10 6 leukocytes (median, 80,150 copies/10 6 leukocytes) and from 1660 to 46,100 copies/ mL (median, 11,395 copies/mL) of plasma (tables 1 and 2). The nonrelapse group consisted of 16 patients (66.7%), among . Data are expressed as copies/10 6 leukocytes or copies/mL of plasma. n = 8 whom the pretreatment CMV DNA levels ranged from 565 to 166,000 copies/10 6 leukocytes (median, 5500 copies/10 6 leukocytes) and from 0 to 33,500 copies/mL (median, 2460 copies/ mL) of plasma. Comparison of median values for CMV load in the pretreatment samples demonstrated a statistically significant difference in values between the relapse and nonrelapse group in the leukocyte fraction (80,150 vs. 5500; ) but P = .007 not in plasma (11,395 vs. 2460; ). Therefore, a pre-P = .267 treatment CMV load у23,100 copies/10 6 leukocytes conveys 81% sensitivity and 75% specificity for the prediction of a subsequent relapse. Conversely, a pretreatment CMV DNA level р5750/10 6 leukocytes was 100% specific, but only 56% sensitive, for the absence of future relapse.
Posttreatment viral loads in the study population ranged from 0 to 94,700 copies/10 6 leukocytes (median, 6274 copies/ 10 6 leukocytes) and from 0 to 117,000 copies/mL (median 11,830 copies/mL) of plasma (table 1). In the relapse group, posttreatment DNA levels ranged from 0 to 94,700 copies/10 6 leukocytes (median, 5810 copies/10 6 leukocytes) and from 0 to 117,000 copies/mL (median, 29,200 copies/mL) of plasma, whereas in the nonrelapse group, all patients had undetectable viral loads in leukocytes and 0 to 3780 copies/mL (median, 0 copies/mL) in plasma ( and , respectively; P ! .0001 P = .0007 table 2). On the basis of these results, it is implied that a posttreatment sample with any level above the detection threshold of 400 copies/10 6 leukocytes or a value у3780 copies/mL of plasma has a 75% sensitivity and 100% specificity and a negative predictive value of 100% for CMV relapse.
When viral load was stratified according to Dϩ/RϪ versus non-Dϩ/RϪ patients, CMV loads in both the pretreatment and posttreatment leukocyte samples were significantly higher among the Dϩ/RϪ patients (83,740 and 15,057 copies/10 6 leukocytes) than among non-Dϩ/RϪ patients (8280 and 0 copies/ 10 6 leukocytes); and , respectively. Similar P ! .001 P = .0014 observations from pre-and posttreatment plasma samples were seen between Dϩ/RϪ (21,666 and 30,467 copies/mL, respectively;
) and non-Dϩ/RϪ (2393 and 360 copies/mL, P = .0040 respectively;
) patients. This difference in viral load P = .0009 that is observed between both epidemiologic risk groups may explain the tight association between primary CMV infection and relapsing CMV disease previously identified [2] .
Discussion
Since the implementation of different strategies to prevent CMV disease during the last few years, such as universal prophylaxis and preemptive therapy, the natural history as well as the clinical presentation and manifestations of CMV infection or disease following solid organ transplantation have been altered. How these changes affect the process of determining a definitive duration and intensity of antiviral treatment is unknown. Moreover, the conventional approach of terminating treatment on clinical resolution of CMV-associated symptoms and/or lack of CMV viremia is obviously imperfect, as evidenced by the high rate of relapse episodes (up to 33%) in studies done before [1, 2] and after (present study) the availability of effective antiviral prophylaxis. Importantly, the form of clinical presentation in this study does not adequately predict the level of viral replication or the risk of developing CMV relapsing disease, thus arguing against the use of clinical parameters to guide antiviral therapy once the natural history of CMV infection may have been modified.
The suitability of a microbiologic marker, such as viremia, for monitoring therapeutic response is greatly diminished because CMV viremia may become rapidly negative after the initiation of intravenous ganciclovir [11] , and its detection by different culture-or antigen-based techniques is subject to fluctuations in the leukocyte content of a blood sample and differences in laboratory processing and handling. These shortcomings make PCR technology an attractive alternative for clinical purposes. However, in solid organ transplant patients, CMV detected by qualitative PCR assays can persist for months despite effective antiviral therapy, limiting the clinical usefulness of qualitative CMV PCR for this purpose [5, 9, [12] [13] [14] . In this regard, the precise quantitation of CMV DNA, rather than qualitative PCR, may be of greater value in virologic monitoring [5, 8, 15] .
This study was aimed at clarifying the clinical role of quantifying CMV DNA by means of a reproductive and automated assay for a number of clinical uses. Its value as a monitoring tool during antiviral treatment, a determinant of the adequacy of treatment, and a predictor for CMV disease relapse is demonstrated. Despite a relatively small sample size, the cohort studied represents a cross-section of the transplant population with its inherent complexity: different types of organ transplants, each with different immunosuppressive and viral prophylaxis regimens and with various forms of CMV infections and disease. On the basis of this heterogeneity and the use of an automated standardized assay, we expect that conclusions from this study should be applicable to a variety of solid organ transplant patients and institutions. Last, the results of this
